PBMs Costing Medicare & Beneficiaries More for Drugs
On February 1st, 2017
WASHINGTON, D.C. – February 1, 2017 – A new White Paper by the law firm of Frier Levitt, LLC examines the ongoing practice by pharmacy Benefit Managers (PBMs) to increase corporate profits through murky “direct and indirect remuneration” fees (commonly known as “DIR Fees”) charged to community oncology practices, as well as retail and specialty pharmacies (“Pharmacy Providers”). These fees, which have no basis in regulation or law, artificially inflate the costs paid by Medicare beneficiaries for prescription drugs, pushing them into the Medicare Part D “donut hole” faster, fueling rising drug prices, and ultimately adding to the burden on taxpayers.
WASHINGTON, D.C. – February 1, 2017 – A new White Paper by the law firm of Frier Levitt, LLC examines the ongoing practice by pharmacy Benefit Managers (PBMs) to increase corporate profits through murky “direct and indirect remuneration” fees (commonly known as “DIR Fees”) charged to community oncology practices, as well as retail and specialty pharmacies (“Pharmacy Providers”). These fees, which have no basis in regulation or law, artificially inflate the costs paid by Medicare beneficiaries for prescription drugs, pushing them into the Medicare Part D “donut hole” faster, fueling rising drug prices, and ultimately adding to the burden on taxpayers.
No comments have been posted yet.